Published in Eur J Nucl Med Mol Imaging on April 12, 2011
Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics (2012) 1.14
The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol (2012) 0.92
Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging (2015) 0.81
¹²⁴I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy ¹³¹I SPECT/CT. Eur J Nucl Med Mol Imaging (2013) 0.79
Clinical Studies of Nonpharmacological Methods to Minimize Salivary Gland Damage after Radioiodine Therapy of Differentiated Thyroid Carcinoma: Systematic Review. Evid Based Complement Alternat Med (2016) 0.78
Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2016) 0.77
Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer. Eur J Nucl Med Mol Imaging (2016) 0.75
The role of nuclear medicine in differentiated thyroid cancer. Wien Med Wochenschr (2012) 0.75
Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab (2004) 2.86
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med (2003) 1.88
The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med (1962) 1.84
Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med (1992) 1.80
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med (2004) 1.76
An overview of the management of papillary and follicular thyroid carcinoma. Thyroid (1999) 1.72
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery (2000) 1.63
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med (2005) 1.35
Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med (1983) 1.28
Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med (1993) 1.26
Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer (1984) 1.15
Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol (2004) 1.14
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14
Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol (2010) 1.09
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging (2007) 1.08
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging (2004) 1.05
124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin (2007) 1.05
Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer (2010) 1.03
Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging (2002) 1.03
The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 1.02
Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys (1991) 0.99
Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun (2006) 0.97
The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med (2007) 0.95
Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med (2008) 0.94
Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging (1999) 0.92
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.90
The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin (2009) 0.89
Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med (1997) 0.87
Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin (2009) 0.87
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging (2010) 0.87
Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol (2009) 0.86
Tomographic imaging of the human thyroid using 124I. J Clin Endocrinol Metab (1986) 0.86
Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging (2007) 0.85
Investigational study of iodine-124 with a positron camera. Am J Physiol Imaging (1988) 0.85
Frequency of diagnostic dilemmas in 131I whole body scanning. Nuklearmedizin (2003) 0.84
Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging (2008) 0.84
The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging (2009) 0.83
(124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution. Eur J Nucl Med Mol Imaging (2006) 0.83
Thyroid cancer dosimetry using clearance fitting. J Nucl Med (1999) 0.83
Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes (2009) 0.82
Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid (1997) 0.80
In vivo imaging of the human thyroid with a positron camera using 124I. Eur J Nucl Med (1985) 0.80
Use of iodine-124 for the treatment of carcinoma of the thyroid. Acta Unio Int Contra Cancrum (1960) 0.80
Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging (2011) 0.80
A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging (2009) 0.80
Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin (2010) 0.78
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)]. Nuklearmedizin (2004) 0.78
On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.77
131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer (1996) 0.77
Identification of a shine-through artifact in the trachea with (124)I PET/CT. J Nucl Med (2009) 0.77
Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma. Nuklearmedizin (2010) 0.77
Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol (1993) 0.76
Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot (2000) 0.75
Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid (1998) 0.75
Radionuclide therapy dose calculations: what accuracy can be achieved? Eur J Nucl Med (1997) 0.75
Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection. Nuklearmedizin (2009) 0.75
Expression of the sodium iodide symporter in differentiated thyroid cancer: clinical evidence. Nuklearmedizin (2005) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging (2009) 2.67
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging (2007) 2.23
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol (2003) 1.84
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol (2007) 1.59
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med (2012) 1.53
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging (2012) 1.50
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48
Segmentation of PET volumes by iterative image thresholding. J Nucl Med (2007) 1.43
MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging (2008) 1.42
Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging (2009) 1.41
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med (2008) 1.28
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27
Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol (2013) 1.19
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging (2010) 1.17
PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging (2006) 1.15
Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res (2006) 1.14
Comparative Analysis of the Conformations of Symmetrically and Asymmetrically Deca- and Undecasubstituted Porphyrins Bearing Meso-Alkyl or -Aryl Groups. Inorg Chem (1997) 1.14
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab (2002) 1.10
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg (2010) 1.09
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging (2007) 1.08
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med (2012) 1.08
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol (2013) 1.05
Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med (2012) 1.03
German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg (2011) 1.02
TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging (2007) 1.02
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology (2004) 1.01
Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract (2005) 1.00
Lymph node staging with dual-modality PET/CT: enhancing the diagnostic accuracy in oncology. Eur J Radiol (2006) 1.00
SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med (2009) 1.00
Functional brain maps of Tower of London performance: a positron emission tomography and functional magnetic resonance imaging study. Neuroimage (2003) 0.99
Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging (2013) 0.99
Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI. Eur J Radiol (2013) 0.97
Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun (2006) 0.97
Subjective perception of radiation risk. J Nucl Med (2011) 0.95
Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology (2008) 0.95
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int (2014) 0.95
[Subjective perception of radioactivity - no change post successful treatment with radioiodine]. Nuklearmedizin (2009) 0.94
Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology (2013) 0.94
Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development. Eur Radiol (2009) 0.93
Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol (2005) 0.93
Hard templating of nanocrystalline titanium dioxide with chiral nematic ordering. Angew Chem Int Ed Engl (2012) 0.92
Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. J Nucl Med (2007) 0.92
Positron emission tomography/computed tomography improves diagnostics of inflammatory arteritis. Heart Vessels (2005) 0.92
Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol (2011) 0.92
Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging (2007) 0.91
Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging (2005) 0.91
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery (2006) 0.91
Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med (2005) 0.90
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.90
68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging (2011) 0.90
Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol (2005) 0.90
Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl (2006) 0.89
PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am (2007) 0.89
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol (2002) 0.88
The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med (2010) 0.88
Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging (2009) 0.87
Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol (2003) 0.87
Whole-body 18F-FDG PET/CT in the presence of truncation artifacts. J Nucl Med (2006) 0.87
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol (2007) 0.87
Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? Eur J Nucl Med Mol Imaging (2009) 0.87
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging (2010) 0.87
Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med (2007) 0.86
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. J Vasc Interv Radiol (2012) 0.84
Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med (2005) 0.84
Physiological ¹⁸F-FDG uptake by the spinal cord: is it a point of consideration for cancer patients? J Neurooncol (2012) 0.84
(124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution. Eur J Nucl Med Mol Imaging (2006) 0.83